Da Vinci 5 and the Replacement CycleNarrow moat
Intuitive Surgical (ISRG) — moat facet
Half of last year's placements were the new generation, and it raises the service contract without adding a machine to the base.
Intuitive's fifth-generation system is doing two jobs at once: winning new programmes and replacing the fleet it already installed.
Da Vinci 5 received FDA clearance in March 2024 for all specialties indicated for da Vinci Xi except cardiac and pediatric1. By the end of 2025 the installed base was 1,231 systems, and 870 of the year's 1,721 da Vinci placements were the new generation, against 362 in 20242. In the June 2026 quarter it was 246 of 4683.
The technical case is unusually concrete for a generational upgrade. Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi and adds force feedback — instruments that let a surgeon "sense and measure the force exerted on tissue during surgery" — along with new controllers, vibration and tremor controls, a next-generation 3D display, an integrated electrosurgical unit and insufflation, and a redesigned console that allows the surgeon to sit fully upright4. It also connects to the digital portfolio: the My Intuitive app, SimNow, Case Insights and Intuitive Hub.
Commercially the replacement cycle is the quieter benefit. An existing customer upgrading is a placement that requires no new programme, no new training pathway and no new surgeon, and it carries a higher service contract. Intuitive attributes part of 2025's service revenue growth to "favorable product mix, particularly from da Vinci 5 surgical system placements"5.
The constraint is geographic and slow. Outside the United States, Intuitive is "in the midst of a phased launch of our da Vinci 5 surgical system over several quarters", with Europe certified in July 2025 but without force feedback pending a separate certification.
Count da Vinci 5 as a share of placements: 51% in 2025 and 53% in the June quarter. Rising means the fleet is refreshing; the ASP rise from $1.50 million to $1.60 million6 says the market is paying for it.
Da Vinci 5 was roughly half of 2025 placements and carries a higher service contract. The replacement cycle raises revenue per installed system without adding one to the base.
Over half, and each upgrade raises the service contract without adding a machine to the base. When the cycle finishes, systems revenue loses a tailwind that has nothing to do with demand.
Source: Intuitive Surgical Q2 2026 earnings call, July 16, 2026 ↗- ReportedDa Vinci 5 received FDA clearance in March 2024 for all specialties indicated for da Vinci Xi except cardiac and pediatric.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedBy the end of 2025 the installed base was 1,231 systems, and 870 of the year's 1,721 da Vinci placements were the new generation, against 362 in 2024.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedIn the June 2026 quarter it was 246 of 468.Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
- ReportedDa Vinci 5 has more than 10,000 times the computing power of da Vinci Xi and adds force feedback — instruments that let a surgeon "sense and measure the force exerted on tissue during surgery" — along with new controllers, vibration and...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedIntuitive attributes part of 2025's service revenue growth to "favorable product mix, particularly from da Vinci 5 surgical system placements".Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedRising means the fleet is refreshing; the ASP rise from $1.50 million to $1.60 million says the market is paying for it.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
- Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Intuitive Surgical second-quarter 2026 results release (Form 8-K exhibit 99.1)